The Validity and Tolerability of Awake Calibration of the TOF Watch SX Monitor

Neuromuscular Blockade Clinical Trial

— CaliRev  

Official title:

The Validity and Tolerability of Awake Calibration of the TOF Watch SX® Monitor: An Interventional Prospective Single Two-center Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03649672
• Other study ID #: CaliRev
• Status: Terminated
• Phase: N/A
• Start date: October 26, 2018
• Est. completion date: November 9, 2021

Study information

• Verified date: January 2022
• Source: University Hospital, Geneva
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Neuromuscular blocking agents (NMBAs) are frequently used in anesthesia and quantitative monitoring of neuromuscular block is standard care. Normally the calibration of the neuromuscular monitor is done after anesthesia induction to avoid patient discomfort. Under certain circumstances there is no time for the calibration process. In the so-called rapid sequence induction (RSI) the neuromuscular blocking agent has to be injected immediately after the induction agent. As the neuromuscular monitor cannot be calibrated, precise neuromuscular monitoring is not possible, and this is of particular disadvantage, when high doses of non-depolarizing neuromuscular blockers are injected to fasten the onset of neuromuscular block. The primary objective is to validate the measurements of the TOF Watch SX® monitor calibrated in awake patients by comparing them with the measurements obtained with the TOF Watch SX® monitor calibrated after anesthesia induction (Gold standard). The secondary objective is to evaluate the tolerability of the awake calibration process of the TOF Watch SX® monitor.

Description:

Neuromuscular function will be assessed by acceleromyography of the adductor pollicis with a TOF-Watch SX® monitor on both arms. By randomization it will be chosen on which arm the awake calibration will be done. 5 minutes before the awake calibration process the patients will receive 0.2 µg/kg of sufentanil intravenously. Immediately after the end of the calibration process the patients will rate the pain of the calibration process on a visual analog scale from 0 to 10. Anesthesia will then be induced and immediately at loss of consciousness continuous TOF stimulation will be continued every 12s. Then the calibration process on the other arm will be started, followed by continuous TOF stimulation. After having obtained stable baseline measurements with the TOF-Watch SX® monitor, a bolus dose of rocuronium 0.6 mg kg-1 will be administered intravenously. The trachea will be intubated when full neuromuscular block is reached. No additional rocuronium will be given. Both neuromuscular monitors will be linked via a fiber-optic (TOF-Link®) cable with UBS port to a laptop. Specific software will be used to record the measurements (TOF watch SX® monitor, version 2.2). Neuromuscular monitoring will be continued until a normalized TOF ratio of 0.9 has been obtained on both arms. The onset of neuromuscular block and its spontaneous recovery will be recorded and the results obtained on each arm will be compared. Every patient is his own control.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 64
• Est. completion date: November 9, 2021
• Est. primary completion date: November 9, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• American Society of Anesthesiologists class I or II
• patients undergoing elective surgery lasting at least 60 minutes under general anesthesia requiring neuromuscular blockade using rocuronium bromide for endotracheal intubation

Exclusion Criteria:

• Patient with a history of allergy or hypersensitivity to rocuronium.
• Patients with neuromuscular disease
• Patients with preoperative medications known to influence neuromuscular function (for instance aminoglycosides, phenytoin, lidocaine)
• Patients with electrolyte abnormalities (for instance, hypermagnesemia)
• Patients with a body mass index <19 or >30 kg m2
• Patient having participated in any clinical trial within 30 days, inclusive, of signing the informed consent form of the current trial
• Patients undergoing interventions that need a continuous deep neuromuscular block
• Pregnant or breast feeding women

Related Conditions & MeSH terms

• Neuromuscular Blockade

Intervention

Device:
• TOF Watch SX
Neuromuscular monitoring via the TOF Watch SX device

Locations

Country	Name	City	State
Switzerland	University Hospital of Geneva, Anesthesia Department	Geneva	Canton Of Geneva
Switzerland	Ospedale Regionale di Lugano	Lugano	Ticino

Sponsors (2)

Lead Sponsor	Collaborator
Christoph Czarnetzki	Hôpital du Valais

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total recovery time	Total duration of the neuromuscular block defined as the time in minutes from start of injection of rocuronium until a normalized TOF ratio of 90%	during the duration of the general anesthesia
Secondary	Onset time	The time in seconds from start of injection of rocuronium until 95% depression of the first twitch (T1) of the TOF	during the duration of the general anesthesia
Secondary	Dur TOFc1	Time in minutes from administration of rocuronium to emergence of the 1st twitch of the TOF	during the duration of the general anesthesia
Secondary	Dur TOF 25%	Time in minutes from administration of rocuronium to emergence of a TOF ratio of 25%	during the duration of the general anesthesia
Secondary	Dur TOF 50%	Time in minutes from administration of rocuronium to emergence of a TOF ratio of 50%	during the duration of the general anesthesia
Secondary	Dur TOF 75%	Time in minutes from administration of rocuronium to emergence of a TOF ratio of 75%	during the duration of the general anesthesia
Secondary	TOF pain: VAS	The pain experienced during the calibration process evaluated by a visual analogue scale from 0 to 10.	before inductin of general anesthesia